Director/PDMR Shareholding

RNS Number : 3334I
Hikma Pharmaceuticals Plc
29 May 2014
 



 

Hikma Pharmaceuticals PLC - LTIP Awards

 

LONDON, 29 May 2014: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) announces that, further to the approval of the Ordinary Shareholders of Hikma obtained at the Company's Annual General Meeting to make awards to the executive directors on 15 May 2014, the Remuneration Committee has made the following conditional awards under the Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan (the "LTIP") to Persons Discharging Managerial Responsibility ("PDMR") of the Company.

 

Awards under the LTIP were made on 29 May 2014 at a price of 1,683 pence per Ordinary Share as follows:

 

Name of PDMR

Said Darwazah

Number of LTIP Shares

57,000

Mazen Darwazah

38,000

 

The shares subject to the LTIP awards will only be released to the participants in three years time, subject to their continued employment and the satisfaction of the performance targets:

·      comparative Total Shareholder Return ("TSR")

·      Sales Growth

·      earnings per share ("EPS") growth

·      return on invested capital ("ROIC")

 

Half of the award is subject to TSR against the Comparator Group and requires at least upper quartile performance to vest in full. The remaining half is split equally between the financial targets and requires sales growth of 13%, EPS growth of 20% and ROIC of 12% to vest in full. Each target is measured individually and is independent of the other targets. Further details on these performance criteria and the LTIP can be found in Hikma's report and accounts for the year ended 31 December 2013 on pages 107 and 109.

 

- ENDS -

 

Enquiries:

 

Hikma Pharmaceuticals PLC 

Peter Speirs                                                                                                     +44 20 7399 2760

Company Secretary

 

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.  In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million. 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSGIGDUCXDBGSC
UK 100

Latest directors dealings